Inhibition of ER Stress Using Tauroursodeoxycholic Acid Rescues Obesity-Evoked Cardiac Remodeling and Contractile Anomalies through Regulation of Ferroptosis
Feng-Juan Li,Miyesaier Abudureyimu,Zeng-Hui Zhang,Jun Tao,Asli F. Ceylan,Jie Lin,Wei Yu,Russel J. Reiter,Milad Ashrafizadeh,Jun Guo,Jun Ren
DOI: https://doi.org/10.1016/j.cbi.2024.111104
IF: 5.168
2024-06-21
Chemico-Biological Interactions
Abstract:Interrupted ER homeostasis contributes to the etiology of obesity cardiomyopathy although it remains elusive how ER stress evokes cardiac anomalies in obesity. Our study evaluated the impact of ER stress inhibition on cardiac anomalies in obesity. Lean and ob/ob obese mice received chemical ER chaperone tauroursodeoxycholic acid (TUDCA, 50 mg/kg/d, p.o.) for 35 days prior to evaluation of glucose sensitivity, echocardiographic, myocardial geometric, cardiomyocyte mechanical and subcellular Ca 2+ property, mitochondrial integrity, oxidative stress, apoptosis, and ferroptosis. Intracellular Ca 2+ governing domains including sarco(endo)plasmic reticulum Ca 2+ -ATPase (SERCA) were monitored by 45 Ca 2+ uptake and immunoblotting. Our results noted that TUDCA alleviated myocardial remodeling (fibrosis, hypertrophy, enlarged LVESD), echocardiographic anomalies (compromised fractional shortening and ejection fraction), cardiomyocyte contractile dysfunction (amplitude and velocity of cell shortening, relengthening time) and intracellular Ca 2+ anomalies (compromised subcellular Ca 2+ release, clearance and SERCA function), mitochondrial damage (collapsed membrane potential, downregulated mitochondrial elements and ultrastructural alteration), ER stress (GRP78, eIF2α and ATF4), oxidative stress, apoptosis and ferroptosis [downregulated SLC7A11, GPx4 and upregulated transferrin receptor (TFRC)] without affecting global glucose sensitivity and serum Fe 2+ in obese mice. Obesity-evoked change in HSP90, phospholamban and Na + -Ca 2+ exchanger was spared by the chemical ER chaperone. Moreover, in vitro results noted that TUDCA, PERK inhibitor GSK2606414, TFRC neutralizing antibody and ferroptosis inhibitor LIP1 mitigated palmitic acid-elicited changes in lipid peroxidation and mechanical function. Our findings favored a role for ferroptosis in obesity cardiomyopathy downstream of ER stress.
pharmacology & pharmacy,biochemistry & molecular biology,toxicology